{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:38:13Z","timestamp":1790271493902,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bayer Consumer Care AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40123-024-01061-3","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T21:02:48Z","timestamp":1734123768000},"page":"211-228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-1165","authenticated-orcid":false,"given":"Anat","family":"Loewenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Sylvanowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried M.","family":"Amoaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Eldem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Finger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Korobelnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mali","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. James","family":"Talks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Focke","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,14]]},"reference":[{"key":"1061_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/ageing\/afac147","volume":"51","author":"J Amuthavalli Thiyagarajan","year":"2022","unstructured":"Amuthavalli Thiyagarajan J, Mikton C, Harwood RH, et al. The UN Decade of healthy ageing: strengthening measurement for monitoring health and wellbeing of older people. Age Ageing. 2022;51:afac147.","journal-title":"Age Ageing"},{"key":"1061_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106\u201316.","journal-title":"Lancet Glob Health"},{"key":"1061_CR3","volume":"14","author":"H Vyawahare","year":"2022","unstructured":"Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022;14: e29583.","journal-title":"Cureus"},{"key":"1061_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000337154","volume":"227","author":"D Veritti","year":"2012","unstructured":"Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica. 2012;227:11\u201320.","journal-title":"Ophthalmologica"},{"key":"1061_CR5","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.15201","volume":"101","author":"RP Gale","year":"2023","unstructured":"Gale RP, Finger RP, Eldem B, et al. The management of neovascular age-related macular degeneration: a systematic literature review of patient-reported outcomes, patient mental health and caregiver burden. Acta Ophthalmol. 2023;101:e26\u201342.","journal-title":"Acta Ophthalmol"},{"key":"1061_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six\u2013week results of the VIEW studies. Ophthalmology. 2014;121:193\u2013201.","journal-title":"Ophthalmology"},{"key":"1061_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","volume":"9","author":"Y Deng","year":"2022","unstructured":"Deng Y, Qiao L, Du M, et al. Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022;9:62\u201379.","journal-title":"Genes Dis"},{"key":"1061_CR8","unstructured":"Genentech, Inc. Lucentis [Prescribing information]. 2024. Available from: https:\/\/www.gene.com\/download\/pdf\/lucentis_prescribing.pdf. Accessed August 2024"},{"key":"1061_CR9","unstructured":"Bayer, AG. Eylea HD [Prescribing information]. 2024. Available from: https:\/\/www.regeneron.com\/downloads\/eyleahd_fpi. Accessed August 2024"},{"key":"1061_CR10","unstructured":"Bayer, AG. Aflibercept (Eylea) Summary of Product Characteristics. 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf. Accessed August 2024"},{"key":"1061_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352.","journal-title":"Lancet"},{"key":"1061_CR12","unstructured":"Novartis. BEOVU [Prescribing information]. 2019. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/beovu.pdf. Accessed August 2024."},{"key":"1061_CR13","unstructured":"Novartis\/Roche. Faricimab (Vabysmo). [Prescribing information]. 2024. Available from: https:\/\/www.gene.com\/download\/pdf\/vabysmo_prescribing.pdf. Accessed August 2024."},{"key":"1061_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52-and 96-week findings from ALTAIR. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"1061_CR15","first-page":"563","volume":"9","author":"PJ Patel","year":"2020","unstructured":"Patel PJ, Jayaram H, Eleftheriadou M, et al. Individualizing therapy for neovascular age-related macular degeneration with Aflibercept (VITAL): two-year prospective, interventional single-centre trial. Ophthalmol Ther. 2020;9:563\u201376.","journal-title":"Interv Single-Centre Trial Ophthalmol Ther"},{"key":"1061_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-020-01468-z","volume":"20","author":"M Weber","year":"2020","unstructured":"Weber M, Dominguez M, Coscas F, et al. Impact of intravitreal aflibercept dosing regimens in treatment-na\u00efve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW. BMC Ophthalmol. 2020;20:1\u20138.","journal-title":"BMC Ophthalmol"},{"key":"1061_CR17","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s00417-021-05073-8","volume":"259","author":"N Eter","year":"2021","unstructured":"Eter N, Hasanbasic Z, Keramas G, et al. PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration. Graefe\u2019s Arch Clin Exp Ophthalmol. 2021;259:2213\u201323.","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"1061_CR18","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1177\/1120672120938565","volume":"31","author":"M Lukic","year":"2021","unstructured":"Lukic M, Eleftheriadou M, Hamilton RD, et al. Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting. Eur J Ophthalmol. 2021;31:1940\u20134.","journal-title":"Eur J Ophthalmol"},{"key":"1061_CR19","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.ophtha.2015.08.014","volume":"122","author":"G Richard","year":"2015","unstructured":"Richard G, Mon\u00e9s J, Wolf S, et al. Scheduled versus pro re nata dosing in the VIEW trials. Ophthalmology. 2015;122:2497\u2013503.","journal-title":"Ophthalmology"},{"key":"1061_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","volume":"3","author":"PG Traine","year":"2019","unstructured":"Traine PG, Pfister IB, Zandi S, Spindler J, Garweg JG. Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a \u201cTreat-and-Extend\u201d regimen. Ophthalmol Retina. 2019;3:393\u20139.","journal-title":"Ophthalmol Retina"},{"key":"1061_CR21","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/s41433-022-02153-9","volume":"36","author":"U Chakravarthy","year":"2022","unstructured":"Chakravarthy U, Armendariz BG, Fauser S. 15 years of anti-VEGF treatment for nAMD: success or failure or something in between? Eye. 2022;36:2232\u20133.","journal-title":"Eye"},{"key":"1061_CR22","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1001\/jamaophthalmol.2020.3989","volume":"138","author":"RP Finger","year":"2020","unstructured":"Finger RP, Puth MT, Schmid M, et al. Lifetime outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. JAMA Ophthalmol. 2020;138:1234\u201340.","journal-title":"JAMA Ophthalmol"},{"key":"1061_CR23","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2147\/OPTH.S409103","volume":"17","author":"G Reitan","year":"2023","unstructured":"Reitan G, Kjellevold Haugen IB, Andersen K, Bragadottir R, Bindesboll C. Through the eyes of patients: understanding treatment burden of intravitreal anti-VEGF injections for nAMD patients in Norway. Clin Ophthalmol. 2023;17:1465\u201374.","journal-title":"Clin Ophthalmol"},{"key":"1061_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40942-022-00425-w","volume":"8","author":"L Wu","year":"2022","unstructured":"Wu L, Bordon AF, Charles M, et al. Intravitreal aflibercept for the treatment of patients with neovascular age-related macular degeneration in routine clinical practice in Latin America: the AQUILA study. Int J Retin Vitr. 2022;8:1\u201310.","journal-title":"Int J Retin Vitr"},{"key":"1061_CR25","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","volume":"36","author":"LN Kim","year":"2016","unstructured":"Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36:1418\u201331.","journal-title":"Retina"},{"key":"1061_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502747","volume":"243","author":"J Mones","year":"2020","unstructured":"Mones J, Singh RP, Bandello F, et al. Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset. Ophthalmologica. 2020;243:1\u20138.","journal-title":"Ophthalmologica"},{"key":"1061_CR27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jamaophthalmol.2021.1660","volume":"139","author":"M Okada","year":"2021","unstructured":"Okada M, Wong TY, Mitchell P, et al. Defining nonadherence and nonpersistence to anti-vascular endothelial growth factor therapies in neovascular age-related macular degeneration. JAMA Ophthalmol. 2021;139:769\u201376.","journal-title":"JAMA Ophthalmol"},{"key":"1061_CR28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2020","unstructured":"Okada M, Mitchell P, Finger RP, et al. Non-adherence or non-persistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2020;128:234\u201347.","journal-title":"Ophthalmology"},{"key":"1061_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272301","volume":"17","author":"S Ozdemir","year":"2022","unstructured":"Ozdemir S, Finkelstein E, Lee JJ, et al. Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration. PLoS ONE. 2022;17: e0272301.","journal-title":"PLoS ONE"},{"key":"1061_CR30","unstructured":"Barometer Leadership Coalition. The Diabetic Retinopathy Barometer Report: Global Findings. Available from: https:\/\/drbarometer.com\/wp-content\/uploads\/2022\/08\/drbarometer_global_report-1.pdf. Accessed August 2024."},{"key":"1061_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.diabres.2017.03.023","volume":"129","author":"D Cavan","year":"2017","unstructured":"Cavan D, Makaroff L, da Rocha FJ, et al. The Diabetic Retinopathy Barometer Study: Global perspectives on access to and experiences of diabetic retinopathy screening and treatment. Diabetes Res Clin Pract. 2017;129:16\u201324.","journal-title":"Diabetes Res Clin Pract"},{"key":"1061_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40123-022-00631-7","volume":"12","author":"SJ Talks","year":"2023","unstructured":"Talks SJ, Daien V, Mitchell P, et al. The patient voice in neovascular age-related macular degeneration: findings from a qualitative study. Ophthalmol Ther. 2023;12:561\u201375.","journal-title":"Ophthalmol Ther"},{"key":"1061_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/PPA.S347713","volume":"16","author":"A Giocanti-Auregan","year":"2022","unstructured":"Giocanti-Auregan A, Garcia-Layana A, Peto T, et al. Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study. Patient Prefer Adher. 2022;16:587\u2013604.","journal-title":"Patient Prefer Adher"},{"key":"1061_CR34","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s00417-016-3384-0","volume":"254","author":"H Senra","year":"2016","unstructured":"Senra H, Ali Z, Balaskas K, Aslam T. Psychological impact of anti-VEGF treatments for wet macular degeneration-a review. Graefes Arch Clin Exp Ophthalmol. 2016;254:1873\u201380.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1061_CR35","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1055\/a-1473-5713","volume":"239","author":"M Hollaus","year":"2022","unstructured":"Hollaus M, Buhl W, Schmidt-Erfurth U, Sacu S. The challenges of treating neovascular age-related macular degeneration. Klin Monbl Augenheilkd. 2022;239:1033\u201342.","journal-title":"Klin Monbl Augenheilkd"},{"key":"1061_CR36","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1007\/s00417-022-05678-7","volume":"260","author":"A Schmid","year":"2022","unstructured":"Schmid A, Bucher F, Liczenczias E, et al. nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey. Graefes Arch Clin Exp Ophthalmol. 2022;260:3241\u201353.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1061_CR37","first-page":"284","volume":"240","author":"AH Krist","year":"2017","unstructured":"Krist AH, Tong ST, Aycock RA, Longo DR. Engaging patients in decision-making and behavior change to promote prevention. Stud Health Technol Inform. 2017;240:284\u2013302.","journal-title":"Stud Health Technol Inform"},{"key":"1061_CR38","unstructured":"Press release (Regeneron Pharmaceuticals, Inc.). Aflibercept 8 mg positive pivotal results in diabetic macular edema and wet age-related macular degeneration. Presented at AAO 2022. (2022)"},{"key":"1061_CR39","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-01061-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-024-01061-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-01061-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T10:05:16Z","timestamp":1736589916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-024-01061-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,14]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1007\/s40123-024-01061-3","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,14]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anat Loewenstein: Consultant: 4DMT, AbbVie, Alkeus, Annexon, Apellis, Astellas, Bayer Health Care, Beyeonics, Eyepoint, Johnson & Johnson, NotalVision, Novartis, Ocular Therapeutics, Oculis, Ocuphire Pharma, Ocuterra, Opthea, Oxurion, Roche, Syneos; Michelle Sylvanowicz: Employee: Bayer; Winfried M. Amoaku: Advisory board membership: AbbVie, Alcon, Alimera, Allergan, Apellis, Bayer, Bausch\u2009+\u2009Lomb, Bioeq, Novartis, Pfizer; Speaker fees: Alimera, Allergan, Bayer, Novartis, Pfizer; Support for travel: Alimera, Allergan, Bayer, Novartis, Pfizer; Research sponsorship and funding: Allergan, Bayer, Boehringer Ingelheim, CenterVue, Gyroscope, Novartis, Optos; Tariq Aslam: Tariq Aslam is an Editor in Chief of <i>Ophthalmology and Therapy<\/i>, and was not involved in the selection of peer reviewers for the manuscript nor any subsequent editorial decisions. Consultant: Novartis, Bayer, Laboratoires, Th\u00e9a Pharmaceuticals, Bausch & Lomb, Oraya; Chui Ming Gemmy Cheung: Financial support (to institution): Allergan, Bayer, Boehringer Ingelheim, Novartis, Roche, Topcon, Zeiss; Stock: Avirmax; Bora Eldem: Consultant: Allergan, Bayer, Novartis, Roche; Robert P. Finger: Research grant: CentreVue, Heidelberg Engineering, Novartis, Zeiss; Consultant: Alimera, Allergan, Bayer, Ellex, Inositec, Novartis, Opthea, Roche\/Genentech, Santhera; Support for travel: Novartis; Richard P. Gale: Consultant\/advisory boards: Allergan, Alimera, Bayer, Novartis, Santen; Educational travel grants: Allergan, Bayer, Heidelberg, Novartis; Research grants: Allergan, Bayer, Novartis, Roche; Laurent Kodjikian: Consultant: AbbVie, Alcon, Allergan, Bayer, Krystal Biotech, Novartis, Regeneron, Th\u00e9a; Adrian Koh: Consultant: Allergan, Bayer, Carl Zeiss, Heidelberg, Novartis, Topcon; Jean-Fran\u00e7ois Korobelnik: Consultant: AbbVie, Apellis, Bayer, Eyepoint Pharma, Ocuphire, Roche, Thea, Carl Zeiss Meditec; Member of DSMB for Alexion, Novo Nordisk, Opthea; Xiaofeng Lin: Consultant: Bayer; Paul Mitchell: Consultant: Allergan, Bayer, Novartis; Steering Committee member: Bayer; Moira Murphy: Employee: Exploristics, Ltd.; Mali Okada: Non-financial support and personal fees: Bayer; Ian Pearce: Lecture fees: Allergan, Bayer, Heidelberg, Novartis; Consultant: Allergan, Alimera, Bayer, Novartis; Support for travel: Allergan, Bayer, Novartis; Francisco J. Rodriguez: Consultant: Bayer, Novartis, Roche; Speaker: Bayer, Novartis, Roche; Research funding: Novartis; Jude Stern: Employee: The International Agency for the Prevention of Blindness; S. James Talks: Advisory board member, speaker fees, and research support: Bayer, Novartis; research grants: Boehringer Ingelheim, Roche; Consultant: Bayer; David T. Wong: Grants\/research support: Bayer, Novartis, Roche; Consultant: Alcon, Allergan, Bausch Health, Bayer, Novartis, Topcon, Zeiss; Equity: Arctic DX; Tien Yin Wong: Clinical trial grants: Allergan, Bayer, Boehringer Ingelheim, Genentech, Merck, Novartis, Oxurion (formerly ThromboGenics), Roche, Samsung Bioepis, NMRC Singapore, Novartis Singapore; Consulting fees\/travel support\/review fees: Allergan, Bayer, Boehringer Ingelheim, Genentech, Merck, Novartis, Oxurion (formerly ThromboGenics), Roche, Samsung Bioepis; Stock: EyRIS, Plano; Focke Ziemssen: Travel grants and personal fees: Allergan, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Clearside, Novartis, Novo Nordisk, MSD Sharp & Dohme, Roche, Optos; Jane Barratt: Consultant: Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The survey was designed and developed according to the Declaration of Helsinki and the World Health Organization\u2019s International Ethical Guidelines for Biomedical Research. While the survey is a Primary Market Research Survey (which does not require ethics committee approval), individual institutions and countries assessed local requirements. Furthermore, informed consent was acquired, no personally identifiable information was collected, and treatment decisions were not informed by response to the survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}